Danielle Brill

Q: How accurate are Danielle Brill's stock ratings?

About 57% of Danielle's ratings were profitable over a one-year hold, with an average return of +4.4% per rating, measured by 13Foresight from historical prices.

Q: How is Danielle ranked?

Danielle Brill is ranked #1289 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Truist Financial

Wall Street Analyst

★★★☆☆

#1289

on 13Foresight · ranked by our own returns

54%

Success Rate

+4.3%

Average Return

38 of 70 calls profitable · -0.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 54% of Danielle Brill's ratings turned a profit when each position was held for 1 year — averaging +4.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

138 Buy 25 Hold 0 Sell

Danielle's Stock Coverage 37 ratings · 2026-08-10

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
CLYM Climb Bio	Aug 07, 2026	BUY	Strong Buy +36.5% avg upside 19 analysts	$25.00 78.65% Upside	-2.8%	·
PRAX Praxis Precision Medicines	Aug 07, 2026	BUY	Strong Buy +49.7% avg upside 24 analysts	$616.00 70.67% Upside	+0.0%	·
IMVT Immunovant	Aug 07, 2026	HOLD	Strong Buy -1.7% avg upside 24 analysts	$30.00 24.87% Downside	+0.0%	·
DNTH Dianthus Therapeutics	Aug 06, 2026	BUY	Strong Buy -11.0% avg upside 29 analysts	$128.00 17.56% Upside	-1.9%	·
RAPP Rapport Therapeutics, Inc.	Aug 06, 2026	BUY	Strong Buy +20.9% avg upside 14 analysts	$56.00 23.07% Upside	-1.9%	·
PVLA Palvella Therapeutics	Aug 05, 2026	BUY	Strong Buy +7.4% avg upside 27 analysts	$207.00 31.17% Upside	-1.7%	·
HRMY Harmony Biosciences Holdings	Aug 05, 2026	HOLD	Strong Buy +25.7% avg upside 13 analysts	$34.00 11.44% Downside	+2.0%	·
VRTX Vertex Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy -12.0% avg upside 62 analysts	$565.00 13.87% Upside	+2.3%	·
ALNY Alnylam Pharma	Aug 04, 2026	BUY	Strong Buy +47.6% avg upside 51 analysts	$315.00 43.76% Upside	-1.8%	·
NBIX Neurocrine	Aug 03, 2026	BUY	Strong Buy +14.9% avg upside 37 analysts	$213.00 30.27% Upside	-1.7%	·
IRON Disc Medicine	Jul 31, 2026	BUY	Strong Buy +12.2% avg upside 21 analysts	$83.00 7.12% Upside	+0.6%	·
WVE Wave Life Sciences	Jul 31, 2026	BUY	Strong Buy +238.3% avg upside 28 analysts	$15.00 145.98% Upside	+10.7%	·
BIIB Biogen	Jul 31, 2026	BUY	Strong Buy +21.6% avg upside 52 analysts	$235.00 12.99% Upside	+2.5%	·
ARGX Argenx Se	Jul 30, 2026	BUY	Strong Buy -9.7% avg upside 47 analysts	$1030.00 19.11% Upside	-0.7%	·
INSM Insmed	Jul 17, 2026	BUY	Strong Buy +33.8% avg upside 37 analysts	—	+24.4%	·
APGE Apogee Therapeutics	May 28, 2026	HOLD	Buy -8.1% avg upside 19 analysts	$81.00 39.96% Downside	+73.0%	·
UPB Upstream Bio, Inc.	May 14, 2026	BUY	Strong Buy +428.3% avg upside 9 analysts	$43.00 493.18% Upside	-17.5%	·
MAZE Maze Therapeutics, Inc.	May 14, 2026	BUY	Strong Buy +124.3% avg upside 12 analysts	—	+8.4%	·
BBIO BridgeBio Pharma	May 11, 2026	BUY	Strong Buy +9.5% avg upside 34 analysts	$102.00 20.80% Upside	+31.3%	·
TECX Tectonic Therapeutic	May 11, 2026	BUY	Strong Buy +80.9% avg upside 24 analysts	$60.00 93.71% Upside	+12.6%	·
QURE uniQure	Dec 10, 2024	BUY	Strong Buy +27.5% avg upside 29 analysts	$9.16 80.18% Downside	+31.6%	·
RGNX RegenXBio	Nov 18, 2024	BUY	Strong Buy +254.0% avg upside 22 analysts	$18.00 67.87% Upside	+10.8%	·
XENE Xenon	Oct 10, 2024	BUY	Strong Buy -1.8% avg upside 28 analysts	$50.00 21.00% Downside	-1.9%	·
AGIO Agios Pharma	Oct 10, 2024	BUY	Strong Buy +88.5% avg upside 29 analysts	$51.00 57.98% Upside	-2.9%	·
PTCT PTC Therapeutics	Oct 10, 2024	HOLD	Strong Buy +10.2% avg upside 29 analysts	—	+72.1%	·
SRPT Sarepta Therapeutics	Oct 10, 2024	BUY	Buy +255.8% avg upside 49 analysts	$150.00 793.98% Upside	-81.9%	·
ACAD ACADIA Pharmaceuticals	Oct 10, 2024	HOLD	Strong Buy +24.5% avg upside 43 analysts	—	+37.9%	·
BMRN BioMarin Pharmaceutical	Oct 10, 2024	BUY	Strong Buy +47.1% avg upside 52 analysts	$79.00 23.86% Upside	-25.1%	·
DNLI Denali Therapeutics	Oct 10, 2024	HOLD	Strong Buy +55.1% avg upside 24 analysts	—	-40.3%	·
KYNB Kyntra Bio	Jun 26, 2023	HOLD	Buy +339.0% avg upside 15 analysts	—	-61.1%	·
PASG Passage Bio	May 16, 2022	BUY	Buy +297.8% avg upside 14 analysts	$10.00 127.34% Upside	-40.8%	·
VERX Vertex	Jun 30, 2021	HOLD	Buy +175.9% avg upside 24 analysts	—	-48.4%	·
KROS Keros Therapeutics	May 27, 2020	BUY	Strong Buy +118.8% avg upside 21 analysts	$45.00 303.59% Upside	+86.0%	·
ALKS Alkermes	Feb 13, 2020	HOLD	Strong Buy -15.5% avg upside 34 analysts	—	+14.6%	·
AXSM Axsome Therapeutics	Dec 16, 2019	BUY	Strong Buy +8.9% avg upside 29 analysts	$125.00 41.21% Downside	+0.8%	·
CBIO Crescent Biopharma	Nov 07, 2019	HOLD	Strong Buy +31.7% avg upside 17 analysts	$5.00 70.30% Downside	·	·
GILD Gilead Sciences	Jul 26, 2016	HOLD	Strong Buy -10.8% avg upside 66 analysts	—	-5.9%	·

🔒 32 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Danielle Brill — Frequently Asked Questions

How accurate are Danielle Brill's stock ratings?

Based on the calls 13Foresight could measure, about 57% of Danielle's ratings were profitable over a one-year hold, with an average return of +4.4% per rating, or -0.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Danielle ranked on 13Foresight?

Danielle Brill is currently ranked #1289 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Danielle cover?

Danielle most recently has ratings on CLYM, PRAX, IMVT, DNTH, RAPP, PVLA, HRMY, VRTX, ALNY, NBIX, IRON, WVE and 25 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Danielle Brill

Rating Distribution

Welcome to 13Foresight!